Synbioff lrh oral microbiome modulator for gum health
SynbiOFF LRh, a heat-killed L. rhamnosus strain, targets oral dysbiosis to support gum health. It disrupts pathogenic biofilms, reduces inflammation, and enhances microbial balance, making it ideal for oral care products.
Overview
SynbiOFF LRh is an innovative oral microbiome modulator designed to promote gum health by addressing oral dysbiosis—a key factor in gingivitis. Utilizing a heat-killed strain of L. rhamnosus, SynbiOFF LRh effectively co-aggregates with harmful microorganisms such as C. albicans, reducing their adhesion to oral surfaces and disrupting pathogenic biofilm formation. This process is crucial for preventing gingival inflammation. Additionally, SynbiOFF LRh exhibits anti-inflammatory properties by lowering pro-inflammatory cytokines, offering a microbiome-friendly solution for daily oral care through products like toothpaste and mouthwash.
Technical specifications
- Microbial Modulation: Co-aggregates with C. albicans to prevent adhesion and biofilm formation.
- Anti-inflammatory Action: Reduces TNF-α levels, thereby directly influencing inflammatory pathways associated with gingivitis.
- Prebiotic-like Effect: Supports beneficial microbial growth, enhancing oral microbiome balance.
- Application Formats: Suitable for incorporation in toothpaste, mouthwash, and topical gel.
- Clinical Validation Plans: Includes formulation, preclinical stability testing, and a controlled clinical trial targeting gingivitis management.
Technology readiness level
SynbiOFF LRh is at TRL 4, having demonstrated functionality through laboratory validation. Plans for further clinical validation are underway, with upcoming trials aimed at confirming efficacy in gingivitis management.
About SynBalance
SynBalance is an Italian biotechnology company and spin-off of ROELMI HPC, specialized in the design, development, and manufacture of high-quality, clinically tested probiotic strains and related microbiome solutions. Operating within the nutraceutical industry, the company utilizes advanced bio-fermentation technology to create proprietary strains of Lactobacilli, Bifidobacteria, and other species. Their R&D process incorporates in-vitro and ex-vivo screening alongside human clinical trials to ensure scientific efficacy, focusing on functional areas such as intestinal health, the gut-skin axis, cardiometabolic risk, immune modulation, and mental health. The company also offers inactivated bacterial strains, known as postbiotics, to expand compatibility with various active ingredients.
Serving both small and multinational partners, SynBalance provides a versatile service model that includes raw material supply, branded and tailor-made formulations, white-label production, and licensing of ready-to-go product concepts. By providing comprehensive product dossiers and regulatory support, the company enables its partners to accelerate time-to-market and develop personalized, evidence-based health strategies. Their business is supported by an integrated management system compliant with international standards, emphasizing quality, safety, and a commitment to modulating the human microbiota to support long-term health and wellness.
delivered to your inbox.